IKT · Inhibikase Therapeutics, Inc.
$2.35
-0.10 (-4.08%)
At close · Aug 20
Market Cap
$341.86M
Shares
139.54M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-11 | — | |
| 10-Q | 2026-08-11 | 2026-06-30 | |
| 8-K | 2026-07-29 | — | |
| 8-K | 2026-07-23 | — | |
| 8-K | 2026-07-14 | — | |
| 8-K | 2026-06-29 | 2026-06-26 | |
| 8-K | 2026-05-12 | — | |
| 10-Q | 2026-05-12 | 2026-03-31 | |
| DEF 14A | 2026-04-30 | 2026-06-26 | |
| 8-K | 2026-04-07 | — | |
| 8-K | 2026-03-26 | — | |
| 10-K | 2026-03-26 | 2025-12-31 | |
| 8-K | 2025-12-19 | — | |
| 8-K | 2025-11-21 | 2025-11-20 | |
| 8-K | 2025-11-20 | — | |
| 8-K | 2025-11-14 | — | |
| 10-Q | 2025-11-14 | 2025-09-30 | |
| 8-K | 2025-08-14 | — | |
| 10-Q | 2025-08-14 | 2025-06-30 | |
| 8-K | 2025-06-30 | 2025-06-27 | |
| 8-K | 2025-05-14 | — | |
| 10-Q | 2025-05-14 | 2025-03-31 | |
| DEF 14A | 2025-05-12 | 2025-06-27 | |
| 10-K/A | 2025-04-25 | 2024-12-31 | |
| 8-K | 2025-04-14 | 2025-04-11 | |
| 10-K | 2025-03-27 | 2024-12-31 | |
| 8-K | 2025-03-27 | — | |
| 8-K | 2025-02-24 | 2025-02-21 | |
| 8-K | 2025-02-18 | 2025-02-13 | |
| 8-K | 2025-01-29 | — | |
| 8-K | 2025-01-06 | 2025-01-03 | |
| 8-K | 2024-12-05 | 2024-12-02 | |
| DEF 14A | 2024-11-18 | 2025-01-03 | |
| 10-Q | 2024-11-14 | 2024-09-30 | |
| 8-K | 2024-10-22 | 2024-10-21 | |
| 8-K | 2024-10-10 | 2024-10-09 | |
| 8-K | 2024-10-09 | — | |
| 10-Q | 2024-08-14 | 2024-06-30 | |
| 8-K | 2024-08-06 | 2024-08-05 | |
| DEF 14A | 2024-06-20 | 2024-08-05 | |
| 8-K | 2024-06-10 | 2024-06-07 | |
| 8-K | 2024-05-20 | — | |
| 10-Q | 2024-05-15 | 2024-03-31 | |
| 8-K | 2024-04-30 | 2024-04-26 | |
| DEF 14A | 2024-04-26 | 2024-06-07 | |
| 8-K | 2024-04-19 | 2024-04-18 | |
| 8-K/A | 2024-04-02 | 2024-01-16 | |
| 10-K | 2024-03-27 | 2023-12-31 | |
| 8-K | 2024-02-07 | — | |
| 8-K | 2024-02-01 | — |
Showing 1–50 of 100 filings
Key facts
CIK
1750149
CUSIP
45719W205
13F (30d)
106 filings
104 filers
Visit website
Investor relations